Immuno-Oncology: Unicorns, China And The Perfect Storm
Executive Summary
There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets.
You may also be interested in...
Checkpoint Inhibitor Deals: Searching For IO Combinations To Unlock Cancer’s Black Box
Merck and Bristol-Myers Squibb's market-dominating checkpoint inhibitors are competing to find the next combination therapy to treat more cancer patients, in more types of cancers. Recent failures and new regulatory pressure, however, may have a cooling effect, even as researchers come full circle with PD-l/PD-L1 and CTL-4 combinations. The race is also on to pull new combinations from emerging cell therapy and precision oncology drug candidates.
Intense Transactional Activity Continues To Propel Biopharma Growth
Outcome Capital analyzed transactional activity by the largest biopharmaceutical companies in the three-and-a-half-year period between January 2017 and June 2020 to reveal development and therapeutic areas trends.
The Emergence Of IO
The approval of first-generation checkpoint inhibitors, Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo in the second half of 2014, catalyzed a wave of deal-making, not only around other checkpoint inhibitors, but also for molecules and technologies that could offer synergistic benefits when used in combination with these drugs.
Need a specific report? 1000+ reports available
Buy Reports